Cost utility of sequential adjuvant trastuzumab for HER2/Neu-positive breast cancer.
Publication
, Journal Article
Reed, SD; Schulman, KA
Published in: Value Health
2009
Duke Scholars
Published In
Value Health
DOI
EISSN
1524-4733
Publication Date
2009
Volume
12
Issue
5
Start / End Page
637 / 640
Location
United States
Related Subject Headings
- Trastuzumab
- Receptor, erbB-2
- Receptor, ErbB-2
- Policy Making
- Humans
- Health Policy & Services
- Female
- Economics, Pharmaceutical
- Drug Costs
- Cost-Benefit Analysis
Citation
APA
Chicago
ICMJE
MLA
NLM
Reed, S. D., & Schulman, K. A. (2009). Cost utility of sequential adjuvant trastuzumab for HER2/Neu-positive breast cancer. Value Health, 12(5), 637–640. https://doi.org/10.1111/j.1524-4733.2009.00564.x
Reed, Shelby D., and Kevin A. Schulman. “Cost utility of sequential adjuvant trastuzumab for HER2/Neu-positive breast cancer.” Value Health 12, no. 5 (2009): 637–40. https://doi.org/10.1111/j.1524-4733.2009.00564.x.
Reed SD, Schulman KA. Cost utility of sequential adjuvant trastuzumab for HER2/Neu-positive breast cancer. Value Health. 2009;12(5):637–40.
Reed, Shelby D., and Kevin A. Schulman. “Cost utility of sequential adjuvant trastuzumab for HER2/Neu-positive breast cancer.” Value Health, vol. 12, no. 5, 2009, pp. 637–40. Pubmed, doi:10.1111/j.1524-4733.2009.00564.x.
Reed SD, Schulman KA. Cost utility of sequential adjuvant trastuzumab for HER2/Neu-positive breast cancer. Value Health. 2009;12(5):637–640.
Published In
Value Health
DOI
EISSN
1524-4733
Publication Date
2009
Volume
12
Issue
5
Start / End Page
637 / 640
Location
United States
Related Subject Headings
- Trastuzumab
- Receptor, erbB-2
- Receptor, ErbB-2
- Policy Making
- Humans
- Health Policy & Services
- Female
- Economics, Pharmaceutical
- Drug Costs
- Cost-Benefit Analysis